Mescaline /
Peyote
NOT MEDICAL ADVICE. For educational purposes only. We are not doctors. Do not stop or modify any prescribed medication based on this content. Many substances discussed are Schedule I controlled substances. Dangerous interactions exist between plant medicines and psychiatric drugs — including serotonin syndrome risk (SSRIs + MAOIs) and seizure risk (Lithium + psychedelics). Always consult qualified healthcare professionals before any action. You proceed entirely at your own risk.
Key Receptors
| Receptor | Action | Clinical Use |
|---|---|---|
| 5-HT2A | Partial agonist | Primary psychedelic; depression, neuroplasticity |
| 5-HT2C | Biased agonist | Mood, appetite neutral |
| D1/D2/D3 | Low-affinity binding | Prosocial, motivation |
| α1A/α2A | Agonist | Arousal, sympathomimetic |
| SERT/NET/DAT | No affinity | No serotonin dump (unlike MDMA/SSRIs) |
Unlike MDMA and SSRIs, mescaline has no serotonin transporter (SERT) affinity — it does not dump serotonin. Its psychedelic action is purely receptor-mediated via 5-HT2A partial agonism, with unique prosocial effects from low-affinity dopamine binding and sympathomimetic arousal from adrenergic agonism.
Same Targets. Opposite Actions.
Latuda (lurasidone) and mescaline share the same receptor targets with opposite actions:
| Receptor | Latuda | Mescaline |
|---|---|---|
| 5-HT2A | Blocks (Ki=0.47nM) | Activates |
| 5-HT7 | Blocks (antidepressant) | Indirect modulation |
| 5-HT1A | Partial agonist | Upstream upregulation |
| D2 | Full antagonist | Low-affinity touch |
| BDNF | Increases over weeks | Acute surge (one session) |
Self-Reported Outcomes
Source: Agin-Liebes et al., ACS Pharmacology 2021 (n=452 naturalistic users). People rated their own symptoms in a survey. This is not a clinical trial and does not show that mescaline treats any condition.
Preparation & Integration Stack
Mescaline-Specific Readiness
How Mescaline Compares
| Medicine | Dep | Anx | PTSD | Addict | Duration | Beginner | Evidence |
|---|---|---|---|---|---|---|---|
| Mescaline/Peyote | Yes | Yes | Yes | Yes | 8–12h | Moderate | Moderate |
| Psilocybin | Yes | Yes | Yes | Yes | 4–6h | Yes | Strong |
| MDMA | Some | Some | Best | Some | 4–6h | Yes | Strong |
| Ketamine | Fastest | Some | Some | Some | 1–2h | Yes (clinical) | Strong/FDA |
| Ayahuasca | Yes | Yes | Yes | Yes | 4–8h | No | Moderate |
| Ibogaine | Some | Some | Yes | Best | 24–36h | No | Moderate |
| San Pedro | Yes | Yes | Yes | Yes | 8–14h | Moderate | Moderate |
| Microdose | Yes | Yes | Some | Yes | Sub-perceptual | Very Yes | Moderate |
Research & References
- Agin-Liebes et al. (2021) ACS Pharmacology — mescaline survey n=452
- Ishibashi et al. (2010) J Pharmacol — lurasidone receptor profile
- Wikipedia / DrugBank — lurasidone Ki values
- PMC6864602 — peyote pharmacokinetics review
- MDPI Molecules 28(24) 7942 (2023) — peyote overview
- Johns Hopkins Psychedelics Center — psilocybin + smoking
- QPS.com / Third Wave — mescaline clinical development